Under the Magnifying Glass: Searching for The Evidence of Pemetrexed in Nonsquamous Nonsmall Cell Lung Cancer

Sindhura Chitikela; Neha Pathak; Prabhat S. Malik

doi:10.1055/s-0041-1735516

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(06): 579-581
DOI: 10.1055/s-0041-1735516

Report on International Publication

Under the Magnifying Glass: Searching for The Evidence of Pemetrexed in Nonsquamous Nonsmall Cell Lung Cancer

Sindhura Chitikela

¹Department of Medical Oncology, Dr. Bhimrao Ramji Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

,

Neha Pathak

¹Department of Medical Oncology, Dr. Bhimrao Ramji Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

,

Prabhat S. Malik

¹Department of Medical Oncology, Dr. Bhimrao Ramji Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

References
1 Ettinger DS, Wood DE, Aisner DL. et al. NCCN guidelines insights: non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw 2021; 19 (03) 254-266
2 Clinical practice living guidelines – metastatic non-small-cell lung cancer. Accessed June 2, 2021 at: https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer
3 Scagliotti GV, Parikh P, von Pawel J. et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26 (21) 3543-3551
4 Patel JD, Socinski MA, Garon EB. et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 2013; 31 (34) 4349-4357
5 Zinner RG, Obasaju CK, Spigel DR. et al. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 2015; 10 (01) 134-142
6 Niho S, Kunitoh H, Nokihara H. et al; JO19907 Study Group. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 2012; 76 (03) 362-367
7 Johnson DH, Fehrenbacher L, Novotny WF. et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22 (11) 2184-2191
8 Zhou C, Wu Y-L, Chen G. et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase iii study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol 2015; 33 (19) 2197-2204
9 Sandler A, Gray R, Perry MC. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355 (24) 2542-2550
10 Yadav A, Malik PS, Khurana S. et al. An open-label randomized controlled trial comparing the efficacy and safety of pemetrexed-carboplatin versus (weekly) paclitaxel-carboplatin as first-line chemotherapy in advanced non-squamous non-small cell lung cancer. Oncology 2021; 99 (06) 389-396
11 Belani CP, Ramalingam S, Perry MC. et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 2008; 26 (03) 468-473
12 Ramalingam S, Perry MC, La Rocca RV. et al. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer 2008; 113 (03) 542-546